Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“18 hours from MIA to Korea means plenty of time to read! So many WCLC26 abstracts beyond the plenary sessions worth exploring. Here’s what I’ll be reading on the journey – because the science doesn’t stop at the plenaries! Oral Abstracts-Part I.
SUNDAY, SEPTEMBER 13, 2026
3:15 PM KST, OA04.02
MDT-BRIDGE
Neoadjuvant durvalumab + chemo in stage IIB-IIIB NSCLC
Presenter: Martin Reck
Location: Auditorium, 3F
3:15 PM KST, OA04.04
Divarasib (NAUTIKA1)
Neoadjuvant divarasib in resectable KRAS G12C+ NSCLC
Presenter: Jamie E. Chaft
Location: Auditorium, 3F
4:45 PM KST, OA05.01
Tarlatamab (DeLLphi-309)
Extended-interval dosing in SCLC
Presenter: Jonathan Goldman
Location: Room 103, Grand Ballroom, 1F
4:45 PM KST, OA05.02
LB2102: DLL3-targeted CAR-T
Phase 1 study in relapsed/refractory SCLC or LCNEC
Presenter: A. Chiappori
Location: Room 103, Grand Ballroom, 1F
4:45 PM KST, OA03.02
Breathomics-based Screening
Risk stratification for pre-imaging triage of lung cancer
Presenter: Jianqi Zheng
Location: OA03 Session
MONDAY, SEPTEMBER 14, 2026
12:00 PM KST, OA08.04
Non-Invasive Prediction of Spread Through Air Spaces in Stage I Lung Adenocarcinoma Using CT-based Virtual PET (CPT-STAS): A Multicenter Study
Location: Room 101, Grand Ballroom, 1F
12:00 PM KST, OA10.01
Phase 1 Global Study of Iza-Bren in Patients With Metastatic EGFR-mutated NSCLC: Results of the Randomized Dose Expansion Cohort
Presenter: A. Spira
Location: Room E5, Conference Room E, 3F
12:00 PM KST, OA10.03
Sac-TMT in Pts With Previously Treated Advanced NSCLC With Actionable Genomic Alterations Other Than Classic EGFR Mutations
Presenter: W. Fang
Location: Room E5, Conference Room E, 3F
5:00 PM KST, OA12.01
Efficacy and Safety of GFH375 in Advanced KRASG12D Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Location: Room 101, Grand Ballroom, 1F
5:00 PM KST, OA12.04
A Single-Arm Phase 2 Study of First-Line Amivantamab, Lazertinib, Pemetrexed in EGFR-mutant NSCLC: AMIGO-1 (LACOG 0821)
Location: Room E5, Conference Room E, 3F.”
Other articles about WCLC26 on OncoDaily.